BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25993147)

  • 21. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.
    Kasajima A; Konukiewitz B; Schlitter AM; Weichert W; Klöppel G
    Virchows Arch; 2022 Feb; 480(2):359-368. PubMed ID: 34499237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of gastric and duodenal neuroendocrine tumors.
    Sato Y; Hashimoto S; Mizuno K; Takeuchi M; Terai S
    World J Gastroenterol; 2016 Aug; 22(30):6817-28. PubMed ID: 27570419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms.
    Gonzalez RS
    Surg Pathol Clin; 2020 Sep; 13(3):377-397. PubMed ID: 32773190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan.
    Ito T; Lee L; Hijioka M; Kawabe K; Kato M; Nakamura K; Ueda K; Ohtsuka T; Igarashi H
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):574-7. PubMed ID: 25689058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.
    Garbrecht N; Anlauf M; Schmitt A; Henopp T; Sipos B; Raffel A; Eisenberger CF; Knoefel WT; Pavel M; Fottner C; Musholt TJ; Rinke A; Arnold R; Berndt U; Plöckinger U; Wiedenmann B; Moch H; Heitz PU; Komminoth P; Perren A; Klöppel G
    Endocr Relat Cancer; 2008 Mar; 15(1):229-41. PubMed ID: 18310290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic Neuroendocrine Tumors.
    Salaria SN; Shi C
    Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
    Langfort R; Rudziński P; Burakowska B
    Pneumonol Alergol Pol; 2010; 78(1):33-46. PubMed ID: 20162517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.
    Neychev V; Kebebew E
    Int J Surg Oncol; 2017; 2017():6424812. PubMed ID: 28593056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.
    Klöppel G
    Visc Med; 2017 Oct; 33(5):324-330. PubMed ID: 29177160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revised classification of neuroendocrine tumors of the lung, pancreas and gut.
    Capella C; Heitz PU; Höfler H; Solcia E; Klöppel G
    Digestion; 1994; 55 Suppl 3():11-23. PubMed ID: 7698533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease.
    Hendifar AE; Marchevsky AM; Tuli R
    J Thorac Oncol; 2017 Mar; 12(3):425-436. PubMed ID: 27890494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathologic Classification of Neuroendocrine Neoplasms.
    Klimstra DS
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):1-19. PubMed ID: 26614366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.
    Matsuoka S; Koizumi T; Otsuki K; Tanaka Y; Kanda S; Ide S; Mishima S; Takeda T; Miura K; Eguchi T; Hamanaka K; Shimizu K
    Cancer Epidemiol; 2022 Apr; 77():102116. PubMed ID: 35144127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
    Schnabel PA; Junker K
    Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists.
    Gadducci A; Carinelli S; Aletti G
    Gynecol Oncol; 2017 Mar; 144(3):637-646. PubMed ID: 28057354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.
    Halperin DM; Kulke MH; Yao JC
    Annu Rev Med; 2015; 66():1-16. PubMed ID: 25341008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
    Oberg K
    Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.